$TCRX
TScan Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$0.331
▼-0.66%-$0.002
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateTScan Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is TCRX down today? It is at $0.331 (-0.66%), and our scanner flagged it 30 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment TCRX spikes, and full due diligence on TCRX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $TCRX 30 times in the last 30 days. Create a free account to track $TCRX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on TCRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for TCRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +6K 0.03% of company | added <0.1% | 8.02M | $6K at $0.900 | Dec 23, 25 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +76K 0.3% of company | added 1.0% | 8.01M | $68K at $0.900 | Dec 22, 25 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +80K 0.3% of company | added 1.0% | 7.94M | $72K at $0.900 | Dec 19, 25 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +1.20M 5.0% of company | added 18% | 7.95M | $1.4M at $1.20 | May 20, 25 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +1.39M 5.8% of company | added 26% | 6.75M | $1.7M at $1.20 | May 19, 25 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +100K 0.4% of company | added 1.9% | 5.36M | $290K at $2.90 | Dec 13, 24 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +32K 0.1% of company | added 0.6% | 5.26M | $96K at $3.01 | Dec 12, 24 |
Lynx1 Capital Management Lp Beneficial Owner (10%) | Bought (open market) | +947 | added <0.1% | 5.23M | $4K at $4.34 | Nov 15, 24 |
Klencke Barbara Director | Bought (open market) | +5K 0.02% of company | added 13% | 45K | $26K at $5.29 | Sep 23, 24 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on TCRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for TCRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
TCRX last traded at $0.331, down 0.66% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
TScan Therapeutics, Inc. Common Stock (TCRX) is next expected to report earnings on Wednesday, November 11, 2026, about 52 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The TCRX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged TCRX 30 times in the last 30 days.
TCRX (TScan Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $7M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge TCRX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$TCRX discussion
Sign in to ask a question or join the discussion.